Investing.com -- Kardigan Inc.’s initial public offering is expected to price at the top of its marketed range or above on Wednesday, Bloomberg reported.
The clinical-stage cardiovascular disease specialist’s offering has attracted demand for multiple times the available shares, the report said. The IPO has drawn anchor-type orders from long-only investors.
The developer of precision medicines for cardiovascular diseases is seeking to raise up to $373.3 million by offering 23.3 million shares priced between $14 and $16 each.
Shares are set to begin trading on the Nasdaq Global Market on Thursday under the symbol KARD.
JPMorgan Chase & Co. Jefferies Financial Group Inc., Leerink Partners and Toronto-Dominion Bank are working on the offering.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates KARD alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if KARD is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?